Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2006-08-08
2006-08-08
Parkin, J. S. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S188100, C424S208100
Reexamination Certificate
active
07087375
ABSTRACT:
The present invention is directed to the field of HIV resistance to RT inhibitors and methods of determining the levels and mechanisms of action of HIV resistance. The methods of the present invention may be accomplished using a novel in vitro assay that provides a reaction well comprising a template for an HIV RT enzyme, a primer, a detectable dNTP substrate, an HIV RT inhibitor, and a ribonucleotide chosen from ATP and GTP or a pyrophosphate. The RT activity is determined by measuring the amount of the detectable dNTP substrate that is incorporated into the template, and the level and/or mechanism of resistance of HIV to the HIV RT inhibitor is determined using the RT activity. The methods may also be used for designing new therapies, screening for new drugs and treatments, and determining the role of mutations in observed resistance.
REFERENCES:
patent: 5985215 (1999-11-01), Sakazume et al.
patent: 6046056 (2000-04-01), Parce et al.
patent: WO 99/30154 (1999-06-01), None
patent: WO 99/67639 (1999-12-01), None
Ekstrand, D. H. L., et al., 1996, “A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive-product detection, with special references to human-immunodeficiency-virus isolation”, Biotechnol. Appl. Biochem. 23:95-105.
Meyer, P. R., et al., 1999, “A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase”, Mol. Cell 4:35-43.
Arion, D., et al., 1998, “Phenotypic mechanism of HIV-1 resistance to 3′-Azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant view reverse transcriptase”, Biochem. 37:15908-15917.
Ueno, T., et al., 1995, “Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates”, J. Biol. Chem. 270(4):23605-23611.
Larder, B. A. and D. K. Stammers, 1999, “Closing in on HIV drug resistance”, Nature Struct. Biol. 6(2):103-106.
Larder, B. A. et al., 1999, “A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance”, Antimicrob. Agents Chemother. 43(8):1961-1967.
Kellam, P, et al., 1992, “Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine”, Proc. Natl. Acad. Sci. USA 89:1934-1938.
Arion et al., “Phenotypic Mechanism of HIV-1 Resistance to 3′-Azido-3′-Deoxythymidine (AZT): Increased Polymerization Procesivity and Enhanced Sensitivity to Pyrophosphate of the Mutant Viral Reverse Transcriptase,”Biochemistry, 37, pp. 15908-15917 (1998).
Canard et al., “Enhanced Binding of Azidothymidine-Resistant Human Immunodeficiency Virus 1 Reverse Transcriptase to the 3′-Azido-3′-Deoxythymidine 5′-Monophosphate-terminated Primer,”The Journal of Biological Chemistry, vol. 273, 23, pp. 14596-14604 (1998).
Carroll et al., “Sensitivity of HIV-1 Reverse Transcriptase and Its Mutant to Inhibition by Azidothymidine Triphosphate,”Biochemistry, 33, pp. 2113-2120 (1994).
Coffin, J.M., “HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy,”Science, vol. 267 (1995).
Ekstrand et al., “A Sensitive Assa for the Quantification of Reverse Transcriptase Activity Based on the Use of Carrier-Bound Template and Non-Radioactive-Product Detection, with Special Reference to Human-Immunodeficiency-Virus Isolation,” vol. 23, pp. 95-105 (1996).
Furman et al., “Phosphorylation of 3′-Azido-3′ -Deoxythymidine and Selective Interation of the 5′-Triphosphate with Human Immunodeficiency Virus* Reverse Transcriptase,”Proc. Natl. Acad. Sci. USA, vol. 83, pp. 8333-8337 (1986).
Harada et al., “Infection of HTLV-III/LAV in HTL-1-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay,”Science, vol. 229, pp. 563-567 (1985).
Harrigan et al., “Significance of Amino Acid Variation at Human Immunodeficiency Virus Type 1 Reverse Transcriptase Residue 210 for Zidovudine Susceptibility,”Journal of Virology, vol. 70, No. 9, pp. 5930-5934 (1996).
Hertogs et al., “A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs,”Antimicrobial Agents and Chemotherapy, vol. 42, 2, pp. 269-276 (1998).
Huang et al., “Structure of a Covalently Trapped Catalytic Complex of HIV-1 Reverse Transcriptase: Implications for Drug Resistance,”Science, vol. 282, pp. 1669-1675 (1998).
Kellam et al., “Recombinant Virus Assay: A Rapid, Phenotypic Assay for Assessment of Drug Susceptibility of Human Immunodeficiency Virus Type 1 Isolates,”Antimicrobial Agents and Chemotherapy, vol. 38, 1, pp. 23-30 (1994).
Kellam et al., “Fifth Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Contributes to the Development of High-Level Resistance to Zidovudine,”Proc. Natl. Acad. Sci. USA, vol. 89, pp. 1934-1938 (1992).
Krebs et al., “Single-Step Kinetics of HIV-1 Reverse Transcriptase Mutants Responsible for Virus Resistance to Nucleoside Inhibitors Zidovudine and 3-TC,”Biochemistry, 36, pp. 10292-10300 (1997).
Lacey et al., “Biochemical Studies on the Reverse Transcriptase and Rnase H Activities from Human Imunodeficiency Virus Strains Resistant to 3′ -Azido-3′ deoxythymidine*,”The Journal of Biological Chemistry, vol. 267, 22, pp. 15789-15794 (1992).
Larder et al., Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT),Science, vol. 246, pp. 1155-1158 (1989).
Larder et al., “A Family of Insertion Mutations Between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance,”Antimicrobial Agents and Chemotherapy, vol. 43, No. 8, p. 1961-1967 (1999).
Larder et al., “Quantitative Detection of HIV-1 Drug Resistance Mutations by Automated DNA Sequencing,”Nature, vol. 365, pp. 671-675 (1993).
Larder et al., “Related Functional Domains in Virus DNA Polymerases,”The EMBO Journal, vol. 6, 1, pp. 169-175 (1987).
Lardner et al., “HIV with Reduced Sensivity to Zidovudine (AZT) Isolated During Prolonged Therapy,”Science, vol. 243, pp. 1731-1734 (1989).
Lennerstrand et al., “Application of a Chain Termination Assay for Characterization of Reverse Transcriptase from AZT-Resistant HIV Isolates,”Antiviral Chemistry&Chemotherapy, vol. 7, 6, pp. 313-320 (1996).
Meyer et al., “A Mechanism of AZT Resistance: An Increase in Nucleotide-Dependent Primer Unblocking by Mutant HIV-1 Reverse Transcriptase,”Molecular Cell, vol. 4, pp. 35-43 (1999).
Ren et al., “3′ -Azido-3′Deoxythymidine Drug Resistance Mutations in HIV-1 Reverse Transcriptase can Induce Long Range Conformational Changes,”Proc. Natl. Acad. Sci. USA, vol. 95, pp. 9518-9523 (1998).
Schinazi et al., “Mutations in Retroviral Genes Associated with Drug Resistance,”International Antivitarl News, vol. 5, 8, pp. 129-142 (1997).
Shao et al., “A Non-Radioactive Microtitre Plate Reverse Tranascriptase (RT) Assay, Based on Immobilized Template, for Screening of RT Activity Inhibitors and Evaluation of their Mode of Action,”Antiviral Chemistry and Chemotherapy, vol. 8, 2, pp. 149-159 (1997).
Shirasaka et al., “Emergence of Human Immunodeficiency Virus Type 1 variants with Resistance to Multiple Dideoxynucleosides in Patients Receiving Therapy with Dideoxynucleosides,”Pr
Larder Brendan
Lennerstrand Johan
Parkin J. S.
Ren Yunling
LandOfFree
Method for determining the mechanism of HIV RT inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for determining the mechanism of HIV RT inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for determining the mechanism of HIV RT inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3628689